New drug for OCD enters Phase II clinical trial
Emotional disorders are common among Americans, many of whom buy Effexor to relieve their symptoms of anxiety and depression.
Emotional disorders are common among Americans, many of whom buy Effexor to relieve their symptoms of anxiety and depression. Recently, a new drug called TO-2061 has entered Phase II of clinical testing to determine its efficacy for treatment of obsessive compulsive disorder (OCD).
The illness affects up to 2 percent of individuals in the U.S. and can lead to a significantly decreased quality of life. Although many established medications such as Effexor have successfully improved patients' well-being, some people may not respond to such drugs. As a result, TO-2061 was created to help address this problem.
"There is no FDA-approved treatment for this population of non-responders," said principal investigator Eric Hollander of the Albert Einstein College of Medicine. "A new therapeutic to help OCD patients who inadequately respond to approved medications has the potential to address an important unmet medical need."
The scientists are now working to confirm their positive results in order to improve symptoms for this subset of individuals with OCD.
Those who have this condition may benefit from purchasing approved drugs from a Canadian internet pharmacy, which can remove the added stress of high expenses.
|
